Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT

Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT

Background Interstitial lung disease frequently complicates systemic autoimmune disorders including scleroderma, idiopathic inflammatory myositis and mixed connective tissue disease, resulting in considerable morbidity and mortality. Based on the results of trials undertaken in scleroderma, cyclopho...

Full description

Bibliographic Details
Main Authors: Toby M Maher, Veronica A Tudor, Peter Saunders, Fernando Zanghelini, Carlota Grossi Sampedro, Georgios Xydopoulos, Michael Gibbons, Sophie V Fletcher, Christopher P Denton, Maria Kokosi, Rachel K Hoyles, Helen Parfrey, Elisabetta A Renzoni, Athol U Wells, Deborah Ashby, Richard J Fordham, Matyas Szigeti, Philip L Molyneaux
Format: Article
Language:English
Published: NIHR Journals Library 2024-02-01
Series:Efficacy and Mechanism Evaluation
Subjects:
systemic sclerosis
idiopathic inflammatory myositis
mixed connective tissue disease
pulmonary fibrosis
forced vital capacity
rituximab
cyclophosphamide
lung diseases
interstitial
economic evaluation
quality of life
recital study
scleroderma
idiopathic inflammatory myopathy
progressive pulmonary fibrosis
autoimmune disease
Online Access:https://doi.org/10.3310/LYWQ8541

Internet

https://doi.org/10.3310/LYWQ8541

Similar Items